NCT06842238 Descriptive Study of the Initial Management of Young Children With Moderate Acute BRONCHiotitis With Home Hospitalisation
| NCT ID | NCT06842238 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Elsan |
| Condition | Bronchiolitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-06-14 |
| Primary Completion | 2027-02-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-06-14 with a primary completion date of 2027-02-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The occurrence of a first episode of acute bronchiolitis in an infant or young child (3 months-2 years) always represents a medical event that generates stress for parents and in some cases for the primary care physician when it is necessary to decide on the child's orientation for treatment. Each year, during the winter season, this pathology affects 30% of infants under two years old (480,000 annual cases in France), generates approximately 30,000 hospitalizations and exposes to an overall mortality risk of 0.08%. According to the recommendations of the HAS (2019), moderate bronchiolitis does not require systematic hospitalization and can be managed in a Home Hospitalization (HAD) context. When the child's examination data do not find signs of severity, the SpO2 measurement is greater than 92% and the family context allows for return home, HAD management is a reasonable option and represents an alternative to the classic scheme of assessing the level of severity by the emergency department and subsequent hospitalization if necessary. HAD management is carried out within the framework of a very structured "patient pathway", codified and supervised by the pediatric teams and doctors of this department. This patient pathway concerns children with a moderate form of bronchiolitis without oxygen requirements at the time of inclusion. This must be 48 hours from the onset of the child's respiratory clinical signs. The main objective of this study is to describe the need for oxygen therapy for a young child with moderate acute bronchiolitis syndrome during home hospitalization (HAD) care.
Eligibility Criteria
Inclusion Criteria: * Any infant with moderate bronchiolitis according to the HAS definition (except for the SpO2 criterion which must be greater than or equal to 92% to avoid the patient being on oxygen therapy upon admission) * Age \> 2 months and ≤ 2 years * Respiratory syndrome for 48 hours * Infant with a first episode of bronchiolitis * Referral of the general practitioner/treating pediatrician for home hospitalisation care * Parents' agreement for the choice of home hospitalisation care * Non-opposition or free and informed consent of both parents to the use of the child's health data Exclusion Criteria: * Patient not receiving health protection * Comorbidities: congenital heart disease with shunt, chronic pulmonary pathology including bronchopulmonary dysplasia, neuromuscular pathology, immune deficiency, multiple disabilities Congenital heart disease * Refusal of one or both parents for the proposed pathway * Doubts about the parents' understanding of the nature of home hospitalisation care * Severe bronchiolitis or with saturation \< 92% * Moderate bronchiolitis but evolving for less than 48 hours * Cases of psychiatric pathologies or depressive syndrome diagnosed in the parents.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06842238 clinical trial?
This trial is open to participants of all sexes, aged 2 Months or older, up to 2 Years, studying Bronchiolitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06842238 currently recruiting?
Yes, NCT06842238 is actively recruiting participants. Contact the research team at recherche.na@elsan.care for enrollment information.
Where is the NCT06842238 trial being conducted?
This trial is being conducted at Poitiers, France.
Who is sponsoring the NCT06842238 clinical trial?
NCT06842238 is sponsored by Elsan. The trial plans to enroll 40 participants.